Increasing diabetes prevalence is boosting demand for SGLT2 inhibitor drugs market
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Empagliflozin, Dapagliflozin And Canagliflozin Market In 2026, And How Will Its Value Evolve By 2030?
The empagliflozin, dapagliflozin, and canagliflozin market size has consistently grown in recent years. It is anticipated to increase from $9.84 billion in 2025 to $10.07 billion in 2026, reflecting a compound annual growth rate (CAGR) of 2.4%. This historical expansion can be attributed to type 2 diabetes prevalence, oral diabetes drug adoption, updates in clinical guidelines, heightened cardiovascular risk awareness, and lifestyle disease growth.
The market for empagliflozin, dapagliflozin, and canagliflozin is projected to experience consistent expansion in the coming years, anticipated to reach a value of $11.08 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 2.4%. Factors driving this expansion during the forecast period include the increasing scope of heart failure treatments, growing evidence for renal protection, the uptake of diabetes combination therapies, an aging demographic, and an emphasis on managing chronic diseases. Key trends observed within the forecast timeframe encompass the escalating utilization of SGLT-2 inhibitors for type 2 diabetes, broader indications for cardiovascular benefits, a heightened preference for oral antidiabetic medications, an increase in combined diabetes therapies, and a significant emphasis on sustained glycemic management.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Drivers Are Supporting The Empagliflozin, Dapagliflozin And Canagliflozin Market Growth?
The rising incidence of diabetes is projected to fuel expansion in the empagliflozin, dapagliflozin, and canagliflozin market in the future. Diabetes is a chronic health condition characterized by elevated blood glucose levels, resulting either from insufficient insulin production or the body’s impaired ability to use insulin effectively. This growing prevalence of diabetes is linked to several factors, including inactive lifestyles, poor eating habits, genetic factors, urban development, and an aging global demographic, further exacerbated by insufficient healthcare access and increasing obesity levels globally. In the management of diabetes, empagliflozin, dapagliflozin, and canagliflozin function to reduce blood sugar by blocking sodium-glucose co-transporter-2 (SGLT2) within the kidneys, thereby facilitating the elimination of glucose via urine. An illustration of this trend is observed in June 2024, where data from the National Health Service (NHS), a UK-based government department, indicated an increase in diabetes cases among individuals under 40, escalating from 173,166 in 2022 to 216,440 in 2023. This substantial rise underscores a worrying pattern within this demographic, demonstrating a swift expansion of diabetes among younger age groups. Consequently, the expanding occurrence of diabetes is propelling the growth of the empagliflozin, dapagliflozin, and canagliflozin market.
Which Segment Classifications Are Used In The Empagliflozin, Dapagliflozin And Canagliflozin Market Segment Analysis?
The empagliflozin, dapagliflozin and canagliflozin market covered in this report is segmented –
1) By Type: Empagliflozin, Dapagliflozin, Canagliflozin
2) By Application: Type 2 Diabetes Mellitus, Heart Failure, Chronic Kidney Disease, Other Applications
3) By Channel: Hospital, Pharmacy
Subsegments:
1) By Empagliflozin: Standard Empagliflozin, Extended-Release Empagliflozin, Combination Empagliflozin Formulations, Generic Empagliflozin
2) By Dapagliflozin: Standard Dapagliflozin, Extended-Release Dapagliflozin, Combination Dapagliflozin Formulations, Generic Dapagliflozin
3) By Canagliflozin: Standard Canagliflozin, Extended-Release Canagliflozin, Combination Canagliflozin Formulations, Generic Canagliflozin
Which Trends Are Expected To Impact The Empagliflozin, Dapagliflozin And Canagliflozin Market?
Major companies within the empagliflozin, dapagliflozin, and canagliflozin markets are increasingly focusing on developing innovative products, such as pediatric type-2 diabetes treatments, to reach broader patient demographics and expand their influence in diabetes care. Pediatric type-2 diabetes treatment involves managing blood sugar through lifestyle adjustments, medications, and sometimes insulin therapy, all specifically tailored for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Farxiga (dapagliflozin) to enhance glycemic control in pediatric patients aged 10 years and older with type 2 diabetes. This approval was based on positive results from the T2NOW Phase III clinical trial, one of the most extensive pediatric type-2 diabetes trials to date, which demonstrated that Farxiga significantly reduced HbA1c levels compared to placebo. The safety profile of Farxiga in this patient population was consistent with that observed in adults with type-2 diabetes. This milestone is particularly significant due to the previously limited oral treatment options for pediatric type-2 diabetes, underscoring AstraZeneca’s commitment to delivering innovative treatments across cardiovascular, renal, and metabolic diseases.
Which Firms Are Contributing To The Empagliflozin, Dapagliflozin And Canagliflozin Market Ecosystem?
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are AstraZeneca PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., MSN Laboratories Private Limited, Dr Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Johnson & Johnson, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Mitsubishi Tanabe Pharma Corporation, USV Ltd., Takeda Pharmaceutical Company Limited
Get The Full Empagliflozin, Dapagliflozin And Canagliflozin Market Report:
Which Region Has The Greatest Market Share In The Empagliflozin, Dapagliflozin And Canagliflozin Market?
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2025. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Empagliflozin, Dapagliflozin And Canagliflozin Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Empagliflozin, Dapagliflozin And Canagliflozin Market 2026, By The Business Research Company
Isoflavones Market Report 2026
https://www.thebusinessresearchcompany.com/report/isoflavones-global-market-report
Anticoagulant Market Report 2026
https://www.thebusinessresearchcompany.com/report/anticoagulant-global-market-report
Fluoxetine Market Report 2026
https://www.thebusinessresearchcompany.com/report/fluoxetine-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
